A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine

Authors : Merve Cansu Polat, Mehveş Işıklar Ekici, Melike Mehveş Kaplan, Elif Çelikel, Zahide Ekici Tekin, Vildan Güngörer, Cüneyt Karagöl, Nimet Öner, Didem Öztürk, Emine Özçelik, Yasemin Uğur Es, Sultan Nilay Yoğun, Banu Acar
Pages : 38-42
Doi:10.12956/tchd.1514723
View : 65 | Download : 122
Publication Date : 2025-01-21
Article Type : Research Paper
Abstract :Objective: The aim of the this study was to evaluate immunoglobulin A vasculitis (IgAV) patients on colchicine therapy and determine the causative factors leading to the initiation and maintenance of colchicine. Material and Methods: This retrospective study was conducted receiving IgAV patients on colchicine at our clinic between January 2013 and June 2023. Demographic, clinical, and laboratory data of IgAV patients were obtained from their electronic medical records. Results: A total of 33 IgAV patients receiving colchicine, 20 (60.6%) males and 13 (39.4%) females, were included in the study. The mean age at diagnosis of IgAV was 111.6±45.5 months. Colchicine was initiated in 13 (39.4%) patients with persistent rash, 8 (24.2%) with severe gastrointestinal tract involvement, seven (21.2%) with generalized/severe rash, and five (15.2%) with recurrent IgAV. The median elapsed time to colchicine initiation was 30 (10.5-60) days. The median duration of colchicine usage was ten (IQR, 6-54) months. Colchicine treatment was discontinued in 14 patients after a median 6.5 (IQR, 3-11.2) months. At the last visit, 13 (39.4%) patients were receiving colchicine for familial Mediterranean fever (FMF), four (12.1%) for recurrent IgAV, and two (6.1%) for persistent rash. Conclusion: Colchicine should be kept in mind especially in the presence of severe, persistent or recurrent rash. Early initiation of colchicine treatment should be considered in IgAV patients with severe GI tract disease, especially in countries where FMF is common.
Keywords : Colchicine, Immunoglobulin A vasculitis, Leukocytoclastic vasculitis, Recurrence

ORIGINAL ARTICLE URL